Study of blood markers in ALS people taking edaravone
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial studies blood or other lab markers in people with ALS, including different ALS patterns, to better understand how the disease works and responds to treatment with edaravone. You may be helped by close monitoring, and the results may guide future ALS care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ALS that doctors consider definite, probable, or possible
- Your ALS symptoms mainly involve lower motor nerves, upper motor nerves, or speech/swallowing areas
- You are between 18 and 85 years old
- You have not taken edaravone (Radicava) before
- If you take riluzole, your dose must be steady for at least 30 days, or you are currently not taking riluzole
- You are willing to join the study and follow study rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial collects blood and spinal fluid samples from people being checked for ALS. The goal is to find clues (biomarkers) in tiny particles from nerve cells that could help doctors better understand and diagnose ALS.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial uses MRI scans to look for “imaging biomarkers” (scan patterns that may help track ALS). It may help researchers better understand disease changes over time and how ALS progresses.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.